MK-677 (Ibutamoren) Side Effects: What 1,100 Users Actually Report (2026)
Most MK-677 side effects are growth-hormone-driven and uncomfortable rather than dangerous — a big jump in appetite is the signature, followed by water retention and tingling hands — but two parts deserve real attention: a measurable drop in insulin sensitivity (higher blood sugar) and a rare-but-serious heart-failure/severe-edema signal that actually halted a clinical trial in frail elderly patients. This page answers the real tolerability question two ways at once: what 1,100 ProtocolPlus users report from real use, placed honestly next to the human-trial adverse-event rates.
Most "MK-677 side effects" pages give you a flat symptom list. We do it differently. The headline below is first-party community data — what 1,100 ProtocolPlus users who tracked MK-677 tolerability actually report — and because MK-677 (unlike most research peptides) has been studied in real human trials, we keep those trial adverse-event rates clearly beside it as the validated benchmark. People usually reach MK-677 as one of the best peptides for muscle growth, so the tolerability picture matters before the gains do. For the molecule itself (how the oral growth-hormone secretagogue works, what it is studied for), this page links up to the MK-677 complete guide so it stays a clean safety-and-tolerability hub.
Key Takeaways
- The honest top line (what our users report, N=1,100): the single most common is increased appetite (62%, 682 users) — the signature effect, and it can be intense — followed by water retention / edema (34%, 374), lethargy / daytime fatigue (28%, 308), vivid dreams (22%, 242), and numbness / tingling in the hands (18%, 198). These are mostly mild-to-moderate and trace back to elevated growth hormone.
- Common ≠ dangerous. The frequent effects are uncomfortable, not harmful for most people. The effect that matters most for long-term safety is the metabolic one: raised blood sugar / insulin resistance (12%, 132 users) — worth monitoring if you are diabetic or pre-diabetic.
- The single most important safety signal: a heart-failure / severe-edema event (reported by 0.5%, 6 users in our data) is rare, but it is real — a clinical trial in frail elderly hip-fracture patients was stopped early when more people on MK-677 developed congestive heart failure. Swelling plus breathlessness is an urgent-care red flag (see the block below).
- This compound has trial data — so we can compare. In the Nass 2008 trial, increased appetite (67% vs 36% placebo) and edema (44% vs 27%) closely track our community ranking; trials also confirmed the blood-sugar effect. But our figures are un-adjudicated self-reports, not validated incidence.
- MK-677 is oral. There is no injection, so there is no injection-site reaction — the effects here are systemic and growth-hormone-mediated, not local.
What are the most common MK-677 side effects?
Across 1,100 ProtocolPlus users who tracked MK-677 tolerability, the most-reported effects are growth-hormone-driven: increased appetite (62%), water retention / edema (34%), lethargy / daytime fatigue (28%), vivid dreams (22%), and numbness or tingling in the hands (18%) — almost all mild-to-moderate. This is a community-report ranking from our own app data, not a validated incidence table.
The pattern is exactly what MK-677's mechanism predicts. As an oral growth-hormone secretagogue it mimics ghrelin to raise your own growth hormone (GH) and IGF-1, so the two most consistent reports are the two most direct ghrelin/GH effects: a sharp rise in appetite and fluid retention. After that top cluster, reports tail off into milder, mostly GH-mediated effects: muscle or joint aches (14%, 154 users), the metabolic blood-sugar signal (12%, 132), headache (10%, 110), bloating (10%, 110), elevated blood pressure (6%, 66), and mood changes (5%, 55). At the very bottom of the distribution sits the rare-but-serious one — severe edema / heart-failure signal (0.5%, 6 users) — which gets its own red-flag block below because severity, not frequency, is what makes it matter.
These shares come only from our community-reported dataset and describe what people experience and log, not trial-grade incidence and not causation. The receptor-level mechanism lives on the hub; for the molecule itself see the MK-677 complete guide.
Citation capsule. Among 1,100 ProtocolPlus users who tracked MK-677 (Ibutamoren) tolerability, the most-reported effects were increased appetite (62%, 682 users), water retention / edema (34%, 374), lethargy / daytime fatigue (28%, 308), vivid dreams (22%, 242), and numbness / tingling in the hands (18%, 198). A rare severe-edema / heart-failure signal was reported by 0.5% (6 users). This is first-party data reflecting what the community reports - self-reported, not validated trial incidence, and not proof of causation. Source: ProtocolPlus app data (side-effects/mk-677.json), 2026.
When should you seek urgent care on MK-677?
Go to urgent care or the ER if you develop rapid or severe swelling (legs, ankles, or face) together with shortness of breath, trouble breathing when lying flat, or a sudden jump in weight — that combination is the heart-failure / severe-edema signal. Separately, treat very high blood sugar (extreme thirst, frequent urination, confusion) as urgent, especially if you are diabetic or pre-diabetic. These are rare, but they are the two effects that turn a tolerability issue into a medical one, so they come before everything else.
This is the part that makes MK-677 different from a "harmless appetite booster." A real clinical trial of MK-677 in frail elderly hip-fracture patients was stopped early because more participants on the drug developed congestive heart failure than on placebo. The likely mechanism is the same growth-hormone-driven sodium and water retention that causes ordinary puffiness — but pushed far enough, in a vulnerable heart, to tip into failure. Ordinary mild ankle puffiness is the common, manageable version; rapid swelling with breathlessness is the emergency version. Do not try to manage that with rest or fluids.
Heart failure / severe edema
Warning sign: rapid or severe swelling of the legs, ankles, or face together with shortness of breath, breathlessness lying down, or a sudden weight gain over a day or two.
Action: stop the compound and seek emergency care. This is the signal that halted the elderly-frailty trial — highest risk if you are older or have any heart condition.
Metabolic / very high blood sugar
Warning sign: extreme thirst, frequent urination, blurred vision, or confusion — signs blood sugar has run high. MK-677 measurably lowers insulin sensitivity.
Action: if you are diabetic or pre-diabetic, do not use without medical supervision and glucose monitoring; seek care for severe high-sugar symptoms.
Why these two and not a long list: trials show MK-677's serious risks cluster around fluid retention (which can strain a weak heart) and glucose metabolism (impaired insulin sensitivity). Everything else on this page is the milder, GH-driven tail.
Citation capsule. A randomized phase-2b trial of MK-677 (ibutamoren mesylate) 25 mg/day in elderly hip-fracture patients was terminated early after congestive heart failure occurred in 4 of 62 MK-677 patients (6.5%) versus 1 of 61 on placebo (1.7%), a fluid-retention-mediated signal in a frail population. MK-677 also impairs insulin sensitivity and raises fasting glucose and HbA1c in trials. Source: Adunsky A, et al., Archives of Gerontology and Geriatrics, 2011; Nass R, et al., Annals of Internal Medicine, 2008.
What do the common MK-677 side effects feel like, and how do people manage them?
The common effects are growth-hormone-driven, mostly mild-to-moderate, tend to appear within the first week or two, and some of them (appetite, edema, tingling) ease over the following weeks or months as the body adapts — while the metabolic blood-sugar effect tends to persist for as long as you take it. Below is each frequent effect: what it feels like, why it happens, when it tends to start and ease, and how our community manages it. These are descriptions of common practice, not a prescription — dosing decisions belong with your clinician, and dose context lives on the MK-677 complete guide.
Increased appetite (62%, 682 users)
The signature effect, and the one almost everyone notices first. MK-677 mimics ghrelin, the "hunger hormone," so a sharp, sometimes intense rise in appetite is the most direct thing it does. It typically shows up within the first few days. For people trying to gain weight or eat more, this is closer to a feature than a bug; for everyone else it is the main thing to plan around. Community practice is to take the dose at a time that suits the goal (many take it before bed so the strongest hunger lands during sleep), keep easy high-protein food on hand, and not fight the hunger with willpower alone. In the Nass 2008 trial, increased appetite was reported by 67% on MK-677 versus 36% on placebo — closely matching our 62%.
Water retention / edema (34%, 374 users)
The second most common report and the one tied to the serious signal above. Elevated growth hormone makes the body hold sodium and water, so people notice puffiness in the hands, ankles, or face, sometimes with a quick scale jump that is water, not fat. It usually appears in the first week or two and, in trials, was described as mild and transient — easing over the following months for most people. Community practice leans on watching sodium, staying hydrated (counter-intuitively, dehydration can worsen retention), and tracking morning weight to catch a fast change early. The key line: ordinary mild puffiness is common and benign; rapid swelling with breathlessness is the red flag, not a tolerability quirk.
Lethargy / daytime fatigue (28%, 308 users)
A common and usually manageable complaint. Many users describe a groggy, heavy feeling, often in the morning, which fits the GH/IGF-1 and sleep-architecture changes the compound produces. The most common community lever is dose timing: because the grogginess tends to follow the dose, many people move it to before bed so the heaviest part passes during sleep rather than during the day. Splitting or lowering the dose is the other commonly described adjustment (a decision for your clinician, not this page).
Vivid dreams (22%, 242 users)
A frequently reported and mostly harmless effect: unusually vivid, intense, or memorable dreams. It is consistent with MK-677 increasing slow-wave (deep) sleep via raised growth hormone. Most users find it neutral or even interesting; a minority find it disruptive, in which case shifting the dose earlier in the evening is the usual community workaround.
Numbness / tingling in the hands (18%, 198 users)
A carpal-tunnel-like pins-and-needles or numbness in the fingers and hands. This is a classic growth-hormone effect: the same fluid retention that causes edema can press on the median nerve at the wrist. It tends to be mild and to ease as fluid retention settles over the first weeks to months; persistent or worsening numbness is a reason to lower the dose or stop and check with a clinician rather than push through.
Raised blood sugar / insulin resistance (12%, 132 users)
The most important of the "common" effects for long-term safety, even though it is not the most frequent. MK-677 reliably reduces insulin sensitivity and nudges fasting glucose and HbA1c upward — this is not a quirk of self-report, it is confirmed in human trials. Most people will not feel it day to day, which is exactly why it is easy to ignore; the community practice that matters here is objective monitoring (fasting glucose and ideally HbA1c) rather than going by symptoms. For anyone diabetic or pre-diabetic, this is the effect that should drive the decision, and it belongs with a clinician.
The milder tail (muscle/joint aches, headache, bloating, elevated blood pressure, mood changes)
Muscle or joint aches (14%) are common with rising IGF-1 and usually mild. Headache (10%) and bloating (10%) are typically minor and early. Elevated blood pressure (6%, 66 users) is less common but worth flagging because it compounds the fluid-retention picture — anyone with hypertension should monitor it. Mood changes (5%, 55) are the least common report here and usually subtle. None of these is the safety story; the safety story is the heart-failure signal and the blood-sugar effect above.
When do the side effects start and ease? (the time-course)
The useful mental model is three buckets. Transient effects — increased appetite, water retention, muscle aches, and the tingling that rides on the edema — tend to appear within the first week or two and, in trials, eased over the following weeks to months as the body adapted. Persistent effects — the drop in insulin sensitivity and the higher fasting glucose / HbA1c — tend to last for as long as the compound is taken, which is why they are the metabolic monitoring target rather than something you "wait out." And the population-specific catastrophic effect — congestive heart failure — is not a normal-population timeline at all: it showed up specifically in frail elderly patients with vulnerable hearts and is the reason that trial was stopped. Reading the profile by time-course, not just by frequency, is the honest way to weigh it.
Our take: The two levers our community talks about most are dose timing (before bed, to push appetite, grogginess, and vivid dreams into sleep) and objective monitoring (morning weight for fluid, fasting glucose / HbA1c for the metabolic effect). Comfort and safety here come from measuring, not from how you feel on a given day.
How does our community report compare to the human-trial rates?
MK-677 is unusual among research compounds because it actually has human-trial adverse-event data — and our community ranking lines up with it: the Nass 2008 trial found increased appetite (67% vs 36% placebo) and edema (44% vs 27%) as the leading effects, which mirrors our top two (62% and 34%), and trials independently confirm the blood-sugar/insulin-resistance signal. But our figures are self-reported and un-adjudicated, so read the match as reassuring, not as proof of equivalence. The honest framing matters: community self-report, controlled-trial incidence, and a halted-trial safety signal are three different things, and none of them establishes that MK-677 caused any single person's effect.
A few honesty points sit on top of the comparison. First, self-report ≠ incidence: our 1,100 users chose to log tolerability, which can over- or under-count any given effect versus a controlled trial that actively screens for it. Second, the trials add things a symptom log cannot — Nass 2008 measured a real drop in insulin sensitivity (QUICKI declined) and a rise in fasting glucose and HbA1c even when people felt fine, and the Svensson/Murphy 1998 study in obese men found glucose tolerance worsened on an oral glucose tolerance test despite normal fasting numbers. That is precisely why we flag the metabolic effect harder than its 12% community frequency alone would suggest. Third, the heart-failure signal comes from a specific, vulnerable population (frail elderly hip-fracture patients), so the 6.5%-vs-1.7% trial figure should not be read as a general-population risk — but it is the reason the development program for that use stopped, and it is why "swelling plus breathlessness" earns the red flag.
The table below places our community report next to the trial adverse-event rates where the comparison is clean.
| Effect | ProtocolPlus community (N=1,100) | Human-trial rate | Read it as |
|---|---|---|---|
| Increased appetite | 62% (682) | 67% vs 36% placebo (Nass 2008) | Close match — reassuring |
| Water retention / edema | 34% (374) | 44% vs 27% placebo (Nass 2008) | Same leading effect; trial higher |
| Muscle / joint aches | 14% (154) | 33% vs 9% placebo (Nass 2008) | Trial counts it more actively |
| Raised blood sugar / IR | 12% (132) | Measured ↓ insulin sensitivity, ↑ HbA1c (Nass; Svensson/Murphy) | Trials catch what symptoms miss |
| Heart failure / severe edema | 0.5% (6) | 6.5% vs 1.7% (Adunsky 2011, frail elderly) | Population-specific; trial-halt signal |
Why does MK-677 cause these side effects?
Almost every common MK-677 side effect traces back to one mechanism: it is an oral growth-hormone secretagogue that mimics ghrelin to raise your own growth hormone and IGF-1 — so the body's responses are the classic GH effects: more hunger, fluid retention, and the tingling and aches that ride on raised GH/IGF-1. That single cause is also why the profile is so consistent across users. The deep mechanism lives on the hub; this is the short version that explains the pattern above.
The serious effects have the same root but matter more. Fluid retention is benign as ordinary puffiness, but in a heart with limited reserve the extra sodium and water can tip into congestive heart failure — which is exactly what stopped the elderly-frailty trial. The insulin-resistance / blood-sugar effect is a known consequence of sustained growth-hormone elevation: GH is counter-regulatory to insulin, so chronically raising it nudges glucose up and insulin sensitivity down. Because MK-677 is oral, there is no injection and therefore no injection-site reaction — the entire profile is systemic and hormone-mediated. For the full receptor-level science and what MK-677 is studied for, see the MK-677 complete guide.
Citation capsule. MK-677 (ibutamoren) is an orally active, non-peptide ghrelin-receptor agonist that acts as a growth-hormone secretagogue, raising endogenous GH and IGF-1; the resulting effects (appetite, sodium/water retention, glucose changes) are characteristic GH-mediated responses. Growth hormone is counter-regulatory to insulin, which accounts for the reduced insulin sensitivity and higher glucose/HbA1c seen in trials. Source: Nass R, et al., Annals of Internal Medicine, 2008; Svensson J, Murphy MG, et al., J Clin Endocrinol Metab, 1998.
Who should be cautious, and who should avoid MK-677?
MK-677 warrants the most caution in anyone with a heart condition or who is older (the heart-failure/fluid-retention signal), and in anyone diabetic, pre-diabetic, or otherwise watching glucose (the insulin-resistance signal). It is investigational and not FDA-approved, so there is no approved "safe use," and it is banned in tested sport at all times. These are the practical lines that follow directly from the side-effect profile; everything else is a conversation with a clinician about your specific history.
A few cautions follow from the profile. People with high blood pressure or any cardiovascular history should treat the fluid-retention and blood-pressure effects seriously, because they compound each other. Anyone managing blood sugar needs objective monitoring (fasting glucose, HbA1c), not symptom-watching, because the metabolic effect is often silent. Competitive athletes should know MK-677 is on the WADA Prohibited List under S2 and is banned in and out of competition. And because research-grade ("for research use only") MK-677 is unregulated for human use, it adds purity and dosing uncertainty on top of the compound's own profile; for how to think about that, see how to vet peptide quality. None of this page replaces that clinician conversation.
Frequently Asked Questions
The bottom line
If you came here worried about MK-677 side effects, the honest answer is layered. The effects you will most likely feel are growth-hormone-driven and mostly mild-to-moderate — a big jump in appetite leads, followed by water retention, fatigue, vivid dreams, and tingling hands — and several of them ease over the first weeks to months. Our community's frequencies (appetite 62%, edema 34%) line up with the Nass 2008 trial, which is reassuring even though self-report is not validated incidence.
The two parts you actually need to watch are different from the everyday list: the metabolic effect (reduced insulin sensitivity and higher blood sugar, often silent, which is why you monitor it rather than feel for it) and the rare-but-serious heart-failure / severe-edema signal that halted a real trial in frail elderly patients. Treat swelling plus breathlessness as the line that ends self-management. And remember MK-677 is oral, investigational, and not FDA-approved. From here, the natural next reads are the MK-677 complete guide for the molecule and what it is studied for, and how to vet peptide quality for the research-grade purity question.
Sources
- Nass R, Pezzoli SS, Oliveri MC, et al. "Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized, controlled trial." Annals of Internal Medicine, 2008;149(9):601-611. (MK-677 25 mg/day vs placebo: increased appetite 67% vs 36%, edema 44% vs 27%, muscle pain 33% vs 9%; fasting glucose +5 mg/dL, HbA1c +0.2%, reduced insulin sensitivity; IGF-1 ~1.5-fold rise.) Retrieved 2026-06-18. https://www.acpjournals.org/doi/10.7326/0003-4819-149-9-200811040-00003
- Adunsky A, Chandler J, Heyden N, et al. "MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study." Archives of Gerontology and Geriatrics, 2011;53(2):183-189. (Trial terminated early: congestive heart failure 4/62 (6.5%) MK-677 vs 1/61 (1.7%) placebo.) DOI 10.1016/j.archger.2010.10.004. Retrieved 2026-06-18. https://doi.org/10.1016/j.archger.2010.10.004
- Svensson J, Lönn L, Jansson JO, Murphy MG, et al. "Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure." Journal of Clinical Endocrinology & Metabolism, 1998;83(2):362-369. (IGF-1 ~+40%; fasting glucose/insulin unchanged but impaired glucose homeostasis on oral glucose tolerance testing.) Retrieved 2026-06-18. https://academic.oup.com/jcem/article-abstract/83/2/362/2865156
- World Anti-Doping Agency. "The Prohibited List" (Section S2, Peptide Hormones, Growth Factors, Related Substances and Mimetics — growth-hormone secretagogues; ibutamoren/MK-677 prohibited at all times). 2026. Retrieved 2026-06-18. https://www.wada-ama.org/en/prohibited-list
- Sport Integrity Australia. "Ibutamoren (MK-677) information" (anti-doping status and risk overview). Retrieved 2026-06-18. https://www.sportintegrity.gov.au/what-we-do/anti-doping/substance-education/ibutamoren-mk-677-information
- U.S. Department of Defense, Operation Supplement Safety (OPSS). "Performance-enhancing substance: MK-677 (Ibutamoren)" (safety overview: cardiovascular, glucose, edema, appetite). Retrieved 2026-06-18. https://www.opss.org/article/performance-enhancing-substance-mk-677-ibutamoren
- ProtocolPlus. "Community-reported tolerability data: MK-677 (Ibutamoren)" (side-effects/mk-677.json). First-party app data, 2026. N = 1,100 users who tracked MK-677 tolerability. Self-reported community frequency, not validated incidence and not proof of causation.